Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: A randomized, double-blind, placebo-controlled safety trial over 16 weeks
Authors: T. Anekthananon
S. Pukritayakamee
W. Ratanasuwan
P. Jittamala
P. Werarak
P. Charunwatthana
S. Suwanagool
S. Lawpoolsri
K. Stepniewska
P. Sapchookul
P. Puthavathana
C. Fukuda
N. Lindegardh
J. Tarning
N. J. White
N. Day
W. R J Taylor
Mahidol University
Nuffield Department of Clinical Medicine
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Mar-2013
Citation: Journal of Antimicrobial Chemotherapy. Vol.68, No.3 (2013), 697-707
Abstract: Objectives: Long-term chemoprophylaxis using neuraminidase inhibitors may be needed during influenza epidemics but safety data are limited to several weeks. We sought to assess the tolerability of oseltamivir and zanamivir as primary prophylaxis over 16 weeks. Methods: We conducted a parallel group, double blind, 2 (active drug):1 (placebo) randomized trial of oral oseltamivir/ placebo or inhaled zanamivir/placebo over 16 weeks in healthy, Thai hospital professionals at two Bangkok hospitals. The primary endpoint was study withdrawal due to drug-related (possibly, probably, definitely) serious or adverse events (AEs) graded ≥2. Results: Recruited subjects numbered 129 oseltamivir/65 placebo and 131 zanamivir/65 placebo. A total of 102 grade ≥2 AEs were reported or detected in 69 subjects: 23/129 (17.8%) versus 15/65 (23.1%) (P=0.26), and 23/131 (17.6%) versus 8/65 (12.3%) (P=0.28). Intercurrent infections/fevers [26/102 (25.5%)], abnormal biochemistry [25/102 (24.5%)] and gastrointestinal symptoms [18/102 (17.6%)] were the most frequently reported AEs. There were no drug-related study withdrawals. Eight serious AEs were all due to intercurrent illnesses. Laboratory, lung function and ECG parameters were similar between drugs and placebos. Conclusions: Oseltamivir and zanamivir were well tolerated in healthy hospital professionals. Both drugs can be recommended for primary influenza prophylaxis for up to 16 weeks. © The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
ISSN: 14602091
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.